Status:
COMPLETED
Remicade Safety Line (Study P03236)(COMPLETED)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
Brief Summary
The goal of this study is to implement instruments that would increase the treating physician's awareness of the necessary tuberculosis screening when starting a new patient on infliximab (Remicade) t...
Detailed Description
This study used a non-probability sampling method.
Eligibility Criteria
Inclusion
- Patients with active rheumatoid arthritis confirmed with adequate clinical response(ACR) criteria who did not react sufficiently to disease-modifying preparations, including methotrexate, and who are receiving new treatment with infliximab.
Exclusion
- As per Summary of Product Characteristics (SmPC)
Key Trial Info
Start Date :
August 1 2002
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
576 Patients enrolled
Trial Details
Trial ID
NCT00748826
Start Date
August 1 2002
End Date
December 1 2010
Last Update
September 3 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.